Business · 27/01/2000Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Vitravene Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for Vitravene, a human drug product, in response to a patent extension application submitted to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →